Journal article
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms
E Neill, SL Rossell, C Yolland, D Meyer, C Galletly, A Harris, D Siskind, M Berk, K Bozaoglu, F Dark, OM Dean, PS Francis, D Liu, A Phillipou, J Sarris, DJ Castle
Schizophrenia Bulletin | Published : 2022
Abstract
Background and Hypothesis: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet a significant proportion of individuals on clozapine continue to experience disabling symptoms, despite being treated with an adequate dose. There is a need for adjunct treatments to augment clozapine, notably for negative and cognitive symptoms. One such potential agent is the glutathione precursor N-acetylcysteine (NAC). Study Design: A randomized double-blind, multi-center, placebo-controlled trial for clozapine patients with enduring psychotic symptoms (n = 84) was undertaken to investigate the efficacy of adjunctive NAC (2 g daily) for negative symptoms, cognition and qual..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The study was funded by the National Health and Medical Research Council project grant (NHMRC GNT1098442).